In MS patients also developing metabolic syndrome, pioglitazone treatment decreases leptin and increases adiponectin serum levels in association with reduced secretion of pro-inflammatory cytokines by PBMC [122]. This evidence concerns the gene ADIPOQ and metabolic syndrome.